Acute asthma Respiratory Acute asthma
Conditions
Interventions
The children included in the study are divided randomly in two groups
Group A: Participants receive inhaled salbutamol solution (Farcolin respirator solution, PHARCO, Alexandria, Egypt), (0.15ml/kg) plus isotonic magnesium sulfate (magnesium sulfate, EIPICO, Alexandria,
Sponsors
Alexandria University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Children diagnosed as asthmatic according to The Global Initiative for Asthma (GINA) guidelines 2. Aged 5-14 years old 3. Capable of measuring PEFR 4. Presenting with moderate to severe acute exacerbation according to pediatric asthma severity score and PEFR
Exclusion criteria
Exclusion criteria: 1. Severely ill patients requiring immediate hospital care 2. Any evidence of respiratory tract infection or suppurative lung diseases 3. Any history of cardiac, renal or hepatic dysfunction 4. Use of short acting bronchodilator within 8 hours or long acting within 24 hours 5. Use of systemic steroids within 72 hours 6. Children known to have immunodeficiency 7. History of previous asthmatic attacks managed by ICU admissions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Asthma severity is measured using the Pediatric Asthma Severity Score (PASS) at baseline, 20, 40 and 60 minutes post-nebulisation 2. Oxygen saturation is measured using pulse oximetry at baseline, 20, 40 and 60 minutes post-nebulisation 3. Lung function is assessed through measuring peak expiratory flow rate (PEFR) at baseline, 20, 40 and 60 minutes post-nebulisation | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
Egypt
Outcome results
None listed